VRDN logo

VRDN
Viridian Therapeutics Inc

9,464
Mkt Cap
$2.8B
Volume
1.41M
52W High
$34.29
52W Low
$9.90
PE Ratio
-7.20
VRDN Fundamentals
Price
$27.39
Prev Close
$28.20
Open
$27.86
50D MA
$29.82
Beta
1.11
Avg. Volume
1.44M
EPS (Annual)
-$3.32
P/B
4.73
Rev/Employee
$281,146.83
$1,947.18
Loading...
Loading...
News
all
press releases
Hudson Bay Capital Management LP Raises Stake in Viridian Therapeutics, Inc. $VRDN
Hudson Bay Capital Management LP raised its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 46.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 175,251 shares of the company's...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
Key PointsKynam Capital sold 2,957,386 shares of Viridian Therapeutics in the fourth quarter; the estimated trade size was $81.11 million based on quarterly average pricing...
Nasdaq News: Markets·8d ago
News Placeholder
Commodore Capital LP Cuts Stake in Viridian Therapeutics, Inc. $VRDN
Commodore Capital LP reduced its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 34.4% during the third quarter, according to its most recent disclosure with the...
MarketBeat·15d ago
News Placeholder
Viridian Therapeutics, Inc. $VRDN Stock Holdings Reduced by Rosalind Advisors Inc.
Rosalind Advisors Inc. lowered its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 14.3% during the third quarter, according to its most recent Form 13F filing with the SEC...
MarketBeat·17d ago
News Placeholder
Wedbush Reaffirms Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN)
Wedbush reissued an "outperform" rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research report on Wednesday...
MarketBeat·19d ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of Viridian Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·23d ago
News Placeholder
Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN
Propel Bio Management LLC acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the third quarter, according to its most recent filing with the Securities and...
MarketBeat·25d ago
News Placeholder
Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC
Fisher Asset Management LLC lifted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 135.6% during the 3rd quarter, according to the company in its most recent disclosure...
MarketBeat·26d ago
News Placeholder
Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
Royal Bank Of Canada decreased their target price on shares of Viridian Therapeutics from $45.00 to $42.00 and set an "outperform" rating for the company in a research report on Friday...
MarketBeat·1mo ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Misses Expectations By $0.18 EPS
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·1mo ago
<
1
2
...
>

Latest VRDN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.